AMG Schedule for Second Quarter 2025 Earnings Release Amsterdam, 23 July 2025 --- AMG Critical Materials N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") will release its second quarter 2025 financial results on Wednesday, July 30, 2025, at approximately 18:00 CEST. AMG will host a conference call to discuss its financial results for the second quarter of 2025 at 09:00 CEST (08:00 BST / 3:00AM EDT) on Thursday, July 31, 2025. Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. The call-in information is as follows: Toll-free number: 1-800-830-9649 A...
A director at Valneva SE bought 20,000 shares at 2.540EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Valneva annonce la levée de la restriction temporaire de l'Agence européenne des médicaments sur l'utilisation du vaccin contre le chikungunya IXCHIQ® chez les personnes âgées Saint Herblain (France), le 11 juillet 2025 – (Nasdaq: VALN; Euronext Paris: VLA), (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence européenne des médicaments (EMA) allait lever sa restriction temporaire sur la vaccination des personnes âgées de 65 et plus avec le vaccin à dose unique contre le chikungunya IXCHIQ® de Valneva suite à l’achèvement d’une ...
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly Saint Herblain (France), July, 11 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva’s single-dose chikungunya vaccine IXCHIQ® by EMA’s safety committee (PRAC). The committee initiated its review at the beginning of May following the occurrence of serious sid...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.